RecruitingWeight Management

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Eligible age

18+ yrs

Accepts

All genders

Locations

34 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Sponsor: AstraZeneca

You may qualify if…

✓ Legal age of consent and at least 18 years old
✓ Study 1 -
✓ BMI ≥ 30 kg/m2 or
✓ 25 kg/m2 ≤ BMI \< 30 kg/m2 with at least one of the following weight-related comorbidities:
✓ Hypertension
✓ Prediabetes
✓ Dyslipidemia
✓ Cardiovascular disease

You may not qualify if…

✕ Study 1 - Established diagnosis of T1DM or T2DM.
✕ Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:
✕ T1DM
✕ HbA1c ≥ 10% (86 mmol/mol) at the screening visit
✕ Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
✕ Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
✕ History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
✕ History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2